ReviewFrontiers in immunology2023
Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Ablation-immunotherapy synergy in cancer: mechanisms of the abscopal effect, emerging clinical applications, and translational roadmaps for next-generation onco-immunology.Medical oncology (Northwood, London, England) · 2026Review
- Tumor ablation: emerging uses, challenges, and strategic implementation. A green paper by the Network of Expertise in Cancer (JANE-2), High Tech Medical Resources, network on Physical Methods of Tumor Ablation.Radiology and oncology · 2026Review
- [Research Advances in ctDNA-MRD Monitoring in Local Treatment for Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Image-guided radiofrequency ablation for treatment of stage I non-small cell lung cancer in 111 high-risk patients: Analysis of prognostic variables.The Journal of thoracic and cardiovascular surgery · 2026Article
- Targeted therapies in lung cancer: personalizing treatment across the age spectrum.Frontiers in oncology · 2026Review
- Intraoperative Inner Experiences of Patients Undergoing Percutaneous Lung Tumor Radiofrequency Ablation Guided by CT in a Chinese Tertiary Hospital: A Qualitative Study.Patient preference and adherence · 2026Article
- Shape-Sensing Robotic-Assisted Bronchoscopic Microwave Ablation for Primary and Metastatic Pulmonary Nodules: Retrospective Case Series.Diagnostics (Basel, Switzerland) · 2025Article
- [Progress in the Immune Mechanism of Microwave Ablation Therapy for Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- In Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity.Vaccines · 2025Review
- Comparison of the efficacy and adverse events between argon-helium cryoablation and microwave ablation for non-small cell lung cancer: a propensity score matching study.Journal of thoracic disease · 2025Article
- The Impact of the Histologic Types of Lung Cancer on CBC-Derived Inflammatory Markers-Current Knowledge and Future Perspectives.Journal of clinical medicine · 2025Article
- Higher-order thermal modeling and computational analysis of laser ablation in anisotropic cardiac tissue.Biomechanics and modeling in mechanobiology · 2025Article
- Interventional oncology and immunotherapy: current status and future perspectives.Frontiers in immunology · 2025Review
- Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Dynamic Changes in the Immune Microenvironment in Tumor-Draining Lymph Nodes of a Lewis Lung Cancer Mouse Model After Microwave Ablation.Journal of inflammation research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thermal ablation is a promising alternative treatment for lung cancer. It disintegrates cancer cells and releases antigens, followed by the remodeling of local tumor immune microenvironment and the activation of anti-tumor immune responses, enhancing the overall effectiveness of the treatment. Biomarkers can offer insights into the patient's immune response and outcomes, such as local tumor control, recurrence, overall survival, and progression-free survival. Identifying and validating such biomarkers can significantly impact clinical decision-making, leading to personalized treatment strategies and improved patient outcomes. This review provides a comprehensive overview of the current state of research on potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation, including their potential role in lung cancer management, and the challenges and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.